YU596A - Estrogen agonists/antagonists - Google Patents

Estrogen agonists/antagonists

Info

Publication number
YU596A
YU596A YU596A YU596A YU596A YU 596 A YU596 A YU 596A YU 596 A YU596 A YU 596A YU 596 A YU596 A YU 596A YU 596 A YU596 A YU 596A
Authority
YU
Yugoslavia
Prior art keywords
antagonists
estrogen agonists
disease
endometrosis
osteoporosis
Prior art date
Application number
YU596A
Other languages
Serbo-Croatian (sh)
Inventor
O. Cameron Kimberly
A. De Silva Jardine Paul
L. Rosati Robert
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU596A publication Critical patent/YU596A/en
Publication of RS49531B publication Critical patent/RS49531B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Jedinjenja ove formule su korisna za tretman ili sprečavanje gojaznosti, kancera dojke, osteoporeze, endometroze, kardiovaskularnih oboljenja i oboljenja prostate.The compounds of this formula are useful for the treatment or prevention of obesity, breast cancer, osteoporosis, endometrosis, cardiovascular disease and prostate disease.

YU596A 1995-01-09 1996-01-08 Estrogen agonists/antagonists RS49531B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/369,954 US5552412A (en) 1995-01-09 1995-01-09 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Publications (2)

Publication Number Publication Date
YU596A true YU596A (en) 1998-12-23
RS49531B RS49531B (en) 2006-12-15

Family

ID=23457628

Country Status (46)

Country Link
US (8) US5552412A (en)
EP (3) EP0802910B1 (en)
JP (1) JP2972347B2 (en)
KR (1) KR100190727B1 (en)
CN (1) CN1059902C (en)
AP (1) AP592A (en)
AR (1) AR003917A1 (en)
AT (1) ATE214382T1 (en)
AU (1) AU700982B2 (en)
BG (1) BG62256B1 (en)
BR (1) BR9600079A (en)
CA (1) CA2209925C (en)
CO (1) CO4600740A1 (en)
CZ (1) CZ285085B6 (en)
DE (2) DE122009000047I1 (en)
DK (1) DK0802910T3 (en)
EG (1) EG23913A (en)
ES (1) ES2172579T3 (en)
FI (1) FI116525B (en)
HR (1) HRP960010B1 (en)
HU (1) HU224077B1 (en)
IL (4) IL116643A (en)
IS (1) IS1916B (en)
LU (1) LU91599I2 (en)
LV (1) LV11460B (en)
MA (1) MA23768A1 (en)
MY (1) MY115784A (en)
NL (1) NL300405I2 (en)
NO (2) NO305435B1 (en)
NZ (1) NZ280792A (en)
OA (1) OA10254A (en)
PE (1) PE46597A1 (en)
PL (1) PL183474B1 (en)
PT (1) PT802910E (en)
RO (1) RO116275B1 (en)
RS (1) RS49531B (en)
RU (1) RU2130454C1 (en)
SA (1) SA96160584B1 (en)
SG (1) SG47377A1 (en)
SI (1) SI9600004A (en)
SK (1) SK281992B6 (en)
TR (1) TR199600001A2 (en)
TW (1) TW313567B (en)
UA (1) UA46710C2 (en)
WO (1) WO1996021656A1 (en)
ZA (1) ZA9695B (en)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974796B1 (en) 1999-08-17 2005-12-13 Girsh Leonard S Therapeutic compositions for treatment of a damaged tissue
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (en) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition
HN1996000101A (en) 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
CA2206752A1 (en) * 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
ID19392A (en) 1996-08-29 1998-07-09 Lilly Co Eli NAFTIL COMPOUNDS AND MIDDLE MATERIALS AND COMPOSITION AND USE METHODS
CA2215856A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Dihydrobenzofluorene compounds, intermediates, compositions, and methods
CA2215647A1 (en) * 1996-10-24 1998-04-24 Eli Lilly And Company Naphthyl compounds, compositions, and methods
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
WO1998048806A1 (en) * 1997-04-25 1998-11-05 Eli Lilly And Company Indene compounds having activity as serms
CA2287943A1 (en) * 1997-04-30 1998-11-05 Tony Yantao Zhang Processes for preparing benzothiophenes
CA2287922A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company Intermediates and processes for preparing benzo[b]thiophenes
CN1252717A (en) * 1997-04-30 2000-05-10 伊莱利利公司 Intermediates and process for preparing benzo (b) thiophenes
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
CA2231013A1 (en) * 1997-04-30 1998-10-30 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
EP0979075A4 (en) * 1997-04-30 2002-07-24 Lilly Co Eli A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO b]THIOPHENES
WO1999007377A1 (en) 1997-08-07 1999-02-18 Eli Lilly And Company 1-[4-(substituted alkoxy)benzyl]naphthalene compounds having estrogen inhibitory activity
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US6080773A (en) 1997-10-14 2000-06-27 Akzo Nobel, N.V. Benzylamine derivatives which are useful in treating psychiatric disorders
US20020037885A1 (en) * 1999-07-22 2002-03-28 Dijcks Fredericus Antonius Therapeutic compounds
US6384060B1 (en) 1997-12-11 2002-05-07 American Home Products Corporation 2,4,6-trisbstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
AU3352899A (en) * 1997-12-11 1999-07-12 American Home Products Corporation 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
FR2778404B1 (en) * 1998-05-06 2000-06-30 Hoechst Marion Roussel Inc DERIVATIVES OF DIHYDRO OR TETRAHYDRONAPHTALENE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0966968B1 (en) 1998-06-16 2004-05-06 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
PA8471201A1 (en) * 1998-06-16 2000-09-29 Pfizer Prod Inc THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE STROGEN RECEPTOR AND PARATHYROID HORMONE MODULATOR
DE19833786A1 (en) * 1998-07-18 2000-01-20 Schering Ag New diphenyl-benzocycloheptene derivatives, are tissue-selective estrogens and antiestrogens useful e.g. for treating osteoporosis or hormone-dependent tumors or in hormone replacement therapy
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
US6503917B1 (en) 1998-12-10 2003-01-07 Wyeth, Five Giralda Farms 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
EP1163225A1 (en) 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) * 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
YU26700A (en) * 1999-05-24 2002-06-19 Pfizer Products Inc. Process for cis -1-(2-(4-(6-metoxy-2-pheniyl-1,2,3,4-tetrahydronaphtalen-1-yl)phenoksy)etil)pyrrolidine
CN1390126B (en) * 1999-07-06 2012-06-13 恩多研究公司 Use of selective estrogen receptor modulator in preparing medicine for treating obesity or reducing risk of development of obesity
EP1086692A3 (en) * 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications
US7790678B1 (en) 1999-08-17 2010-09-07 Immunopath Profile, Inc. Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use
US20070037777A1 (en) * 2005-08-12 2007-02-15 Immunopath Profile, Inc. Lipid-containing compositions and methods of using them
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CO5271696A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc PROCEDURE TO REDUCE MORBILITY AND RISK OF MORTALITY
CO5271709A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE AND TREATMENT OF AFFECTIONS RESPONDING TO STROGENS
CO5271697A1 (en) 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
CO5251465A1 (en) * 2000-01-26 2003-02-28 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES TO TREAT OSTEOPOROSIS AND REDUCE CHOLESTEROL
AU2001240985B2 (en) * 2000-04-07 2005-08-04 Pfizer Products Inc. Estrogen agonist/antagonist metabolites
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1156120B1 (en) * 2000-05-08 2006-11-22 Pfizer Products Inc. Enzymatic resolution of selective estrogen receptor modulators
DE60101206T2 (en) * 2000-06-01 2004-09-02 Watson Pharmaceuticals, Inc., Corona TRANSDERMAL ADMINISTRATION OF LASOFOXIFEN
AR029538A1 (en) 2000-07-06 2003-07-02 Wyeth Corp PHARMACEUTICAL COMPOSITIONS OF ESTROGEN AGENTS
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
JP2002117407A (en) * 2000-10-10 2002-04-19 Satake Corp Dynamic image retrieval method and device thereof
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
PT1210951E (en) * 2000-11-30 2005-04-29 Pfizer Prod Inc COMPOSITION THAT CONTAINS AGONISTS / ANTAGONISTS OF ESTROGENE AND TESTOSTERONE FOR TARTAMENT OF A HORMONE LEVEL DECLINE TESTOSTERONE
JP2004515494A (en) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ Therapeutic agent
AU2002235348A1 (en) * 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US20020182646A1 (en) * 2001-04-30 2002-12-05 Ke Huazhu Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
EA005949B1 (en) * 2001-05-01 2005-08-25 Пфайзер Продактс Инк. Method for manufacturing a low dose pharmaceutical composition
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
DK1397130T3 (en) 2001-06-20 2007-11-12 Wyeth Corp Substituted Indole Acid Derivatives as Inhibitors of Plasminogen Activator Inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
AU2002365132A1 (en) 2001-10-17 2003-07-15 Bristol-Myers Squibb Company BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-Alpha CONVERTING ENZYME (TACE)
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
PL372727A1 (en) * 2002-03-28 2005-07-25 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US6608212B1 (en) * 2002-06-04 2003-08-19 Pfizer, Inc. Process for preparing vinylaromatic compounds
PA8576201A1 (en) * 2002-07-10 2004-05-26 Pfizer Prod Inc PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO
BR0312675A (en) 2002-07-22 2005-05-03 Lilly Co Eli A compound or a pharmaceutical acid addition salt thereof, methods for treating endometriosis, and for treating uterine leiomyoma
US9315539B2 (en) * 2002-10-01 2016-04-19 Yale University 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer
JP2006510672A (en) 2002-12-10 2006-03-30 ワイス Substituted indoleoxo-acetylaminoacetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
AU2003297727A1 (en) 2002-12-10 2004-06-30 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA05006288A (en) 2002-12-10 2005-08-19 Wyeth Corp Substituted 3-carbonyl-1h.
ATE411288T1 (en) 2002-12-10 2008-10-15 Wyeth Corp ARYL-, ARYLOXY- AND ALKYLOXY-SUBSTITUTED 1H-INDOLE-3-YL-GLYOXYLIC ACID DERIVATIVES INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP4500689B2 (en) 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Selective estrogen receptor modulator
US7332525B2 (en) 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
CA2513432A1 (en) * 2003-01-22 2004-08-05 Pfizer Products Inc. Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
CN1780634A (en) * 2003-04-30 2006-05-31 德比奥法姆股份有限公司 Methods and compositions using gonadotropin hormone releasing hormone
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP1667692A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
MXPA06006810A (en) * 2003-12-17 2006-08-23 Pfizer Prod Inc Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass.
WO2005073205A1 (en) * 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
WO2005073190A1 (en) * 2004-01-29 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
MXPA06011686A (en) 2004-04-08 2006-12-14 Wyeth Corp Bazedoxifene ascorbate as selective estrogen receptor modulator.
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US20090118316A1 (en) * 2004-06-21 2009-05-07 Pfzer Inc. Methods for Augmenting Bone
WO2006023242A1 (en) * 2004-08-17 2006-03-02 Janssen Pharmaceutica N.V. Benzoxazepine derivatives as selective estrogen receptor modulators
AU2005277139A1 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
MX2007002178A (en) 2004-08-23 2007-04-02 Wyeth Corp Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases.
BRPI0514549A (en) 2004-08-23 2008-06-17 Wyeth Corp pyrrol-naphthyl acids as inhibitors of pai-1
KR20070084455A (en) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
EP1856104A1 (en) 2005-01-27 2007-11-21 Wyeth a Corporation of the State of Delaware Processes and compounds for the preparation of substituted naphthylindole derivatives
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
US20100160648A1 (en) * 2005-06-22 2010-06-24 Geraldine Patricia Taber Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride
PL1912650T3 (en) * 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Use of flibanserin in the treatment of obesity
JP2009504762A (en) 2005-08-17 2009-02-05 ワイス Substituted indoles and methods for their use
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5212931B2 (en) * 2006-01-26 2013-06-19 学校法人東京理科大学 Method for producing lasofoxifene and its analogs
PT2021006E (en) * 2006-05-09 2015-11-12 Sprout Pharmaceuticals Inc Use of flibanserin for the treatment of post-menopausal sexual desire disorders
US20090312242A1 (en) * 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
JP2009543839A (en) * 2006-07-14 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of flibanserin to treat sexual disorders in women
CL2007002214A1 (en) 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
WO2008019996A2 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
KR20090045945A (en) * 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 Controlled release system and method for manufacturing the same
JP5498168B2 (en) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー N-((3-Benzyl) -2,2- (bis-phenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular disease
US8304601B2 (en) * 2007-01-23 2012-11-06 Keiko Fujikawa Mouse model for eye disease
CZ2007373A3 (en) * 2007-05-29 2008-12-10 Zentiva, A. S Process for preparing lasofoxifene
US20090062374A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched lasofoxifene
PE20091188A1 (en) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int COMPOUND 1- [2- (4- (3-TRIFLUOROMETIL-PHENYL) PIPERAZIN-1-IL) ETHYL] -2,3-DIHYDRO-1H-BENZIMIDAZOL-2-ONA (FLIBANSERIN), ITS ADDITION SALTS AND PHARMACEUTICAL COMPOSITIONS THAT THEY CONTAIN
JP5558358B2 (en) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド TRANS-clomiphene for metabolic syndrome
WO2009155481A1 (en) * 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
WO2010125578A2 (en) * 2009-04-29 2010-11-04 Glenmark Generics Limited A process for the preparation of lasofoxifene tartrate
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
DE102010030538A1 (en) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
CN102311406A (en) * 2010-06-29 2012-01-11 武汉启瑞药业有限公司 Method for preparing lasofoxifene intermediate
CN102464629A (en) * 2010-11-12 2012-05-23 上海医药工业研究院 Preparation method of 1- {2- [4- (6-methoxy-2-phenyl-3, 4-dihydronaphthalene-1-yl) phenoxy ] ethyl } pyrrolidine
EP2524908A1 (en) 2011-05-20 2012-11-21 LEK Pharmaceuticals d.d. Process for the preparation of alfa-substituted ketones and their application in synthesis of pharmaceutically active compounds
DE102011087987A1 (en) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
CN102643178A (en) * 2012-02-08 2012-08-22 浙江华海药业股份有限公司 Preparation methods of lasofoxifene tartrate and intermediate thereof
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
CN103113323B (en) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 The preparation method of Lasofoxifene tartrate intermediate
WO2015092634A1 (en) * 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
DK3122426T3 (en) 2014-03-28 2023-04-03 Univ Duke Treatment of breast cancer using selective estrogen receptor modulators
EP3981766A1 (en) 2015-05-29 2022-04-13 Eisai R&D Management Co., Ltd. Indazole derivatives useful in the treatment of cancer
JP6920295B2 (en) * 2015-11-09 2021-08-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Tetrahydronaphthalene estrogen receptor modulator and its use
EP3373967B9 (en) 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
JP7241542B2 (en) * 2016-04-08 2023-03-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US20180098963A1 (en) 2016-10-11 2018-04-12 Duke University Lasofoxifene treatment of breast cancer
CN109790141B (en) 2016-11-28 2021-06-11 卫材 R&D 管理有限公司 Salts of indazole derivatives and crystals thereof
KR20200138714A (en) 2018-02-21 2020-12-10 에이아이 테라퓨틱스, 인코포레이티드 Combination therapy with apilimod and glutamate agents
EP3773524A4 (en) 2018-04-10 2021-12-22 Duke University Lasofoxifene treatment of breast cancer
CN109317203B (en) * 2018-12-03 2019-09-03 毕云丽 A kind of preparation method for treating postmenopausal osteoporosis pharmaceutical intermediate
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3396169A (en) * 1966-10-26 1968-08-06 Upjohn Co Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
US3234090A (en) * 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3227730A (en) * 1963-05-01 1966-01-04 Union Carbide Corp Stabilization of lactones
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3293263A (en) * 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3320271A (en) * 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
US3483293A (en) * 1967-12-15 1969-12-09 Upjohn Co Method for controlling birds and rodents
US3875242A (en) 1968-01-02 1975-04-01 Upjohn Co Compounds and process for preparing the same
US3567737A (en) * 1968-01-02 1971-03-02 Upjohn Co Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE4117512A1 (en) * 1991-05-25 1992-11-26 Schering Ag 2-PHENYLBENZO (B) FURANES AND THIOPHENES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5484798A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5532382A (en) * 1995-03-13 1996-07-02 Eli Lilly And Company Benzothiophenes substituted at the 3-carbonyl
US5567828A (en) * 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
UA59384C2 (en) * 1996-12-20 2003-09-15 Пфайзер, Інк. Preventing bone mass loss and recovery thereof by means of prostaglandin agonists
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
CN1599606A (en) * 2001-07-31 2005-03-23 辉瑞产品公司 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
DE102012218742A1 (en) 2012-10-15 2014-04-17 Deere & Company Nachdrescheinrichtung for a combine harvester

Also Published As

Publication number Publication date
UA46710C2 (en) 2002-06-17
LV11460A (en) 1996-08-20
ES2172579T3 (en) 2002-10-01
CO4600740A1 (en) 1998-05-08
SG47377A1 (en) 1998-04-17
AU4091696A (en) 1996-07-18
US6204286B1 (en) 2001-03-20
KR100190727B1 (en) 1999-06-01
AU700982B2 (en) 1999-01-14
DK0802910T3 (en) 2002-05-21
DE69525857D1 (en) 2002-04-18
OA10254A (en) 1997-09-19
JP2972347B2 (en) 1999-11-08
CZ285085B6 (en) 1999-05-12
ZA9695B (en) 1997-07-08
IL130761A0 (en) 2001-01-28
MA23768A1 (en) 1996-10-01
EP0802910B1 (en) 2002-03-13
PL312182A1 (en) 1996-07-22
RS49531B (en) 2006-12-15
TW313567B (en) 1997-08-21
USRE39558E1 (en) 2007-04-10
EP1151998A1 (en) 2001-11-07
PT802910E (en) 2002-07-31
US20010025051A1 (en) 2001-09-27
IL130761A (en) 2000-12-06
BG62256B1 (en) 1999-06-30
IS1916B (en) 2004-02-19
US5552412A (en) 1996-09-03
WO1996021656A1 (en) 1996-07-18
NL300405I1 (en) 2009-11-02
US6441193B1 (en) 2002-08-27
NO960081L (en) 1996-07-10
PL183474B1 (en) 2002-06-28
IL139235A0 (en) 2001-11-25
IL116643A0 (en) 1996-05-14
ATE214382T1 (en) 2002-03-15
LU91599I2 (en) 2009-10-19
FI972903A (en) 1997-07-08
NO2009018I2 (en) 2010-06-28
SI9600004A (en) 1996-10-31
PE46597A1 (en) 1997-11-25
HUP9600056A2 (en) 1998-12-28
BR9600079A (en) 1998-01-27
SA96160584B1 (en) 2005-06-12
IS4316A (en) 1996-07-10
HUP9600056A3 (en) 2000-04-28
NZ280792A (en) 1997-11-24
IL116643A (en) 2000-08-13
EG23913A (en) 2007-12-30
RO116275B1 (en) 2000-12-29
HRP960010B1 (en) 2002-06-30
CN1136562A (en) 1996-11-27
KR960029323A (en) 1996-08-17
NO2009018I1 (en) 2009-09-07
AP9500774A0 (en) 1996-01-31
HU224077B1 (en) 2005-05-30
CN1059902C (en) 2000-12-27
LV11460B (en) 1996-12-20
FI116525B (en) 2005-12-15
NO960081D0 (en) 1996-01-08
US6153622A (en) 2000-11-28
HRP960010A2 (en) 1997-12-31
FI972903A0 (en) 1997-07-08
US20020132816A1 (en) 2002-09-19
AP592A (en) 1997-05-05
EP0802910A1 (en) 1997-10-29
CA2209925C (en) 2000-08-01
EP1411049A1 (en) 2004-04-21
JPH10503215A (en) 1998-03-24
US20100317712A1 (en) 2010-12-16
TR199600001A2 (en) 1996-08-21
DE122009000047I1 (en) 2009-11-05
MX9705145A (en) 1997-10-31
CA2209925A1 (en) 1996-07-18
DE69525857T2 (en) 2002-11-28
MY115784A (en) 2003-09-30
NL300405I2 (en) 2010-03-01
BG100278A (en) 1996-05-31
NO305435B1 (en) 1999-05-31
SK164895A3 (en) 1997-05-07
RU2130454C1 (en) 1999-05-20
SK281992B6 (en) 2001-09-11
CZ5596A3 (en) 1996-10-16
AR003917A1 (en) 1998-09-30

Similar Documents

Publication Publication Date Title
YU596A (en) Estrogen agonists/antagonists
BR0006265A (en) Compound of tetrahydroisoquinolines as estrogen agonists / antagonists
YU21401A (en) Tetrahydropyridoethers
ATE415979T1 (en) TREATMENT WITH ANTI-ERBB2 ANTIBODIES
CY1107862T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ESTEROL PRODUCERS FOR USE IN CANCER TREATMENT
ATE355079T1 (en) TREATMENT OF PROSTATE CANCER WITH ANTI-ERBB2 ANTIBODIES
DE69929345D1 (en) SUBTITLED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS
DE69732868D1 (en) Remedy for itching
DE69942827D1 (en) USE OF EPOTHILONS FOR THE TREATMENT OF CANCER
PT971585E (en) TETRACYCLINE COMPOUNDS IN THE TREATMENT OF CERTAIN TYPES OF CANCER
MX9805253A (en) Vitronectin receptor antagonists.
PL367682A1 (en) Dolastatin 10 derivatives
CR6540A (en) NEMATICIDED TRIFLUOROBUTENS
DE69908397D1 (en) BETULINIC ACID DERIVATIVES FOR THE TREATMENT OF NEUROEKTODERMAL TUMORS
EA200200545A1 (en) ONCOLYTIC COMBINATIONS FOR CANCER TREATMENT
ATE239509T1 (en) CONJUGATES FOR THE TREATMENT OF PROSTATE CANCER
ATE264304T1 (en) DIHYDRONAPHTHALINE DERIVATIVES AND METHOD FOR PRODUCING THE SAME
CU23088A3 (en) TETRA-HYDROPIRIDINE COMPOUNDS.
HK1056692A1 (en) Proteins
DZ2665A1 (en) Conjugates useful for the treatment of prostate cancer.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
ATE339208T1 (en) USE OF PROGESTERONE RECEPTOR INHIBITORS TO TREAT STEROID-RESISTANT BREAST CANCER
ECSP961634A (en) AGONISTS, ESTROGEN ANTAGONISTS
ATE263164T1 (en) BENZOTHIOPHENE